Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979484 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations
A Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01979484: Completed Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers, sponsored by Presidio Pharmaceuticals.
NCT01979484 is a Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01979484, a Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.
Conditions Studied
Interventions
- DRUG PPI-668 capsule
- DRUG PPI-668 tablet
Study Locations (1)
New York
- Buffalo Clinical Research Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01979484 record still lists
NCT01979484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Pharmacokinetic Assessments in Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which PPI-668 capsule is the first listed.
NCT01979484 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01979484 about?
NCT01979484 is a clinical study titled "Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations". This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.
What is the current status of trial NCT01979484?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2013-12.
What conditions does trial NCT01979484 study?
This clinical trial studies the following conditions: Pharmacokinetic Assessments in Healthy Volunteers.
What interventions are being tested in trial NCT01979484?
The interventions under investigation include: PPI-668 capsule (DRUG), PPI-668 tablet (DRUG).
Who is sponsoring clinical trial NCT01979484?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979484 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01979484's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia